New Study Links Ivermectin to ‘Large Reductions’ In COVID-19 Deaths
A recent pre-print review based on peer-reviewed studies has found that using antiparasitic drug ivermectin could lead to “large reductions” in COVID-19 deaths and its use could have a “significant impact” on the pandemic globally.
For the study (pdf), published on June 17 in the American Journal of Therapeutics, a group of scientists reviewed the clinical trial use of ivermectin, which has antiviral and anti-inflammatory properties, in 24 randomized controlled trials involving just over 3,400 participants.
The researchers sought to assess the efficacy of ivermectin in reducing infection or mortality in people with COVID-19 or at high risk of getting it. Using multiple methods of sequential analysis, the researchers concluded with a moderate level of confidence that the drug reduced the risk of death in COVID-19 patients by an average of 62 percent, at a 95 percent confidence interval of 0.19-0.79, in a sample of 2438 patients.